We are delighted to welcome David Loew as the new CEO of Ipsen. A seasoned professional, David’s career has spanned nearly thirty years in the pharmaceutical industry in such companies as Roche and Sanofi. His leadership skills and experience in a range of therapeutic areas, including oncology, neuroscience and consumer healthcare make him a great fit with our mission and values.
David comes to Ipsen from Sanofi Pasteur Vaccines, where he was CEO. During his tenure, he piloted a successful growth strategy via acquisitions and licensing deals. He also undertook a series of transformational initiatives: developing a global pipeline, reinforcing the production strategy to strengthen compliance and increase capacity and building key programs to bring the company to best-practice level across the board.
He started his career in the United States at Coopers & Lybrand and Hewlett Packard in 1990, before joining Roche in 1992. He moved to Sanofi in 2013 as Senior Vice President Commercial Operations Europe.
“I’m very happy to join Ipsen. It’s a great company– built on a solid foundation and with a bright future ahead of it. I’m looking forward to meeting the teams and helping them carry forward the important work they do for patients,” says David.
We are excited to see what the future holds and we wish David all the best in his new role.